ATRC
AtriCure, Inc. [ATRC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ATRC Stock Summary
Top 10 Correlated ETFs
ATRC
Top 10 Correlated Stocks
ATRC
In the News
ATRC Financial details
ATRC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.14 | 4.9 | 6.09 | 7.22 | 8.62 | |
| Net income per share | -0.94 | -1.14 | 1.11 | -1.02 | -0.66 | |
| Operating cash flow per share | -0.42 | -0.47 | -0.31 | -0.48 | 0.1 | |
| Free cash flow per share | -0.74 | -0.6 | -0.52 | -0.85 | -0.81 | |
| Cash per share | 2.18 | 5.8 | 2.64 | 2.65 | 2.96 | |
| Book value per share | 6.58 | 9.79 | 10.73 | 9.99 | 10.07 | |
| Tangible book value per share | -3.12 | 1.17 | 4.57 | 3.99 | 3.61 | |
| Share holders equity per share | 6.58 | 9.79 | 10.73 | 9.99 | 10.07 | |
| Interest debt per share | 2.14 | 1.87 | 1.79 | 1.74 | 1.51 | |
| Market cap | 1.22B | 2.35B | 3.13B | 2.03B | 1.65B | |
| Enterprise value | 1.27B | 2.38B | 3.17B | 2.04B | 1.64B | |
| P/E ratio | -34.72 | -48.7 | 62.42 | -43.69 | -54.3 | |
| Price to sales ratio | 5.29 | 11.35 | 11.42 | 6.14 | 4.14 | |
| POCF ratio | -77.29 | -118.03 | -227.39 | -91.68 | 373.59 | |
| PFCF ratio | -43.65 | -93.33 | -133.15 | -52.02 | -43.99 | |
| P/B Ratio | 4.94 | 5.69 | 6.48 | 4.44 | 3.55 | |
| PTB ratio | 4.94 | 5.69 | 6.48 | 4.44 | 3.55 | |
| EV to sales | 5.5 | 11.51 | 11.54 | 6.18 | 4.12 | |
| Enterprise value over EBITDA | -53.46 | -53.74 | -21.13 | -47.83 | -100.91 | |
| EV to operating cash flow | -80.32 | -119.64 | -229.71 | -92.18 | 371.37 | |
| EV to free cash flow | -45.37 | -94.6 | -134.51 | -52.3 | -43.73 | |
| Earnings yield | -0.03 | -0.02 | 0.02 | -0.02 | -0.02 | |
| Free cash flow yield | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Debt to equity | 0.31 | 0.18 | 0.16 | 0.16 | 0.14 | |
| Debt to assets | 0.14 | 0.1 | 0.12 | 0.13 | 0.1 | |
| Net debt to EBITDA | -2.02 | -0.72 | -0.21 | -0.26 | 0.6 | |
| Current ratio | 2.87 | 6.24 | 3.47 | 3.69 | 3.57 | |
| Interest coverage | -8.06 | -9.05 | -9.62 | -8.56 | -4.49 | |
| Income quality | 0.45 | 0.41 | -0.27 | 0.48 | -0.15 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | -0.11 | -0.29 | 0.25 | -0.13 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.18 | 0.21 | 0.18 | 0.17 | 0.19 | |
| Intangibles to total assets | 0.65 | 0.51 | 0.45 | 0.47 | 0.49 | |
| Capex to operating cash flow | 0.77 | 0.26 | 0.71 | 0.76 | -9.49 | |
| Capex to revenue | -0.05 | -0.03 | -0.04 | -0.05 | -0.11 | |
| Capex to depreciation | -1.3 | -0.55 | -0.93 | -1.44 | -2.84 | |
| Stock based compensation to revenue | 0.08 | 0.11 | 0.1 | 0.09 | 0.09 | |
| Graham number | 11.77 | 15.87 | 16.4 | 15.11 | 12.2 | |
| ROIC | -0.1 | -0.09 | -0.08 | -0.08 | -0.06 | |
| Return on tangible assets | -0.18 | -0.14 | 0.15 | -0.15 | -0.1 | |
| Graham Net | -5.13 | -0.55 | 0.71 | 1.04 | 1.36 | |
| Working capital | 93.24M | 257.6M | 139.63M | 156.82M | 191.68M | |
| Tangible asset value | -117.32M | 49.41M | 205.98M | 182.63M | 167.4M | |
| Net current asset value | -167.38M | 4.59M | 64.52M | 86.52M | 118.48M | |
| Invested capital | 0.31 | 0.18 | 0.16 | 0.16 | 0.14 | |
| Average receivables | 26.62M | 25.6M | 28.08M | 37.86M | 47.6M | |
| Average payables | 12.3M | 13.84M | 15.67M | 19.25M | 23.63M | |
| Average inventory | 25.95M | 32.22M | 37M | 42.45M | 56.91M | |
| Days sales outstanding | 44.35 | 40.91 | 43.94 | 47.17 | 48 | |
| Days payables outstanding | 90.22 | 81.24 | 99.14 | 86.01 | 98.05 | |
| Days of inventory on hand | 177.54 | 223.42 | 207.71 | 198.54 | 243.38 | |
| Receivables turnover | 8.23 | 8.92 | 8.31 | 7.74 | 7.6 | |
| Payables turnover | 4.05 | 4.49 | 3.68 | 4.24 | 3.72 | |
| Inventory turnover | 2.06 | 1.63 | 1.76 | 1.84 | 1.5 | |
| ROE | -0.14 | -0.12 | 0.1 | -0.1 | -0.07 | |
| Capex per share | -0.32 | -0.12 | -0.22 | -0.37 | -0.91 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.92 | 2.03 | 2.18 | 2.12 | 2.29 | |
| Net income per share | -0.09 | -0.14 | -0.11 | -0.2 | -0.21 | |
| Operating cash flow per share | 0 | -0.09 | 0.07 | 0.03 | 0.09 | |
| Free cash flow per share | -0.09 | -0.14 | -0.65 | -0.05 | 0.03 | |
| Cash per share | 2.64 | 2.95 | 2.75 | 2.87 | 2.96 | |
| Book value per share | 9.95 | 9.86 | 9.99 | 9.97 | 10.04 | |
| Tangible book value per share | 3.98 | 3.94 | 3.46 | 3.5 | 3.6 | |
| Share holders equity per share | 9.95 | 9.86 | 9.99 | 9.97 | 10.04 | |
| Interest debt per share | 1.66 | 1.6 | 1.58 | 1.56 | 1.4 | |
| Market cap | 2.04B | 1.91B | 2.28B | 2.03B | 1.66B | |
| Enterprise value | 2.05B | 1.91B | 2.29B | 2.03B | 1.65B | |
| P/E ratio | -122.16 | -73.78 | -111.55 | -56.12 | -42.34 | |
| Price to sales ratio | 23.15 | 20.44 | 22.63 | 20.68 | 15.56 | |
| POCF ratio | 44.3K | -468.53 | 758.45 | 1.34K | 411.34 | |
| PFCF ratio | -493.96 | -290.4 | -75.95 | -964.33 | 1.33K | |
| P/B Ratio | 4.46 | 4.2 | 4.94 | 4.39 | 3.56 | |
| PTB ratio | 4.46 | 4.2 | 4.94 | 4.39 | 3.56 | |
| EV to sales | 23.27 | 20.42 | 22.7 | 20.62 | 15.47 | |
| Enterprise value over EBITDA | -495.3 | -330.17 | -552.92 | -250.54 | -367.09 | |
| EV to operating cash flow | 44.53K | -468.01 | 760.97 | 1.33K | 408.9 | |
| EV to free cash flow | -496.62 | -290.08 | -76.2 | -961.38 | 1.32K | |
| Earnings yield | 0 | 0 | 0 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | -0.01 | 0 | 0 | |
| Debt to equity | 0.16 | 0.17 | 0.16 | 0.16 | 0.14 | |
| Debt to assets | 0.13 | 0.13 | 0.13 | 0.12 | 0.1 | |
| Net debt to EBITDA | -2.65 | 0.37 | -1.83 | 0.77 | 2.19 | |
| Current ratio | 3.69 | 3.81 | 3.33 | 3.06 | 3.57 | |
| Interest coverage | -2.65 | 3.53 | 2.41 | 4.56 | -4.82 | |
| Income quality | -0.01 | 0.63 | -0.59 | -0.17 | -0.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.55 | -0.08 | -0.69 | -0.09 | -0.24 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.16 | 0.16 | 0.17 | 0.21 | 0.2 | |
| Intangibles to total assets | 0.47 | 0.47 | 0.51 | 0.5 | 0.49 | |
| Capex to operating cash flow | -90.67 | 0.61 | -10.99 | -2.39 | -0.69 | |
| Capex to revenue | -0.05 | -0.03 | -0.33 | -0.04 | -0.03 | |
| Capex to depreciation | -1.43 | -0.85 | -9.24 | -0.88 | -0.67 | |
| Stock based compensation to revenue | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Graham number | 4.51 | 5.58 | 4.99 | 6.62 | 6.9 | |
| ROIC | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Return on tangible assets | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | |
| Graham Net | 1.03 | 1.44 | 1.28 | 1.4 | 1.35 | |
| Working capital | 156.82M | 175.85M | 166.57M | 170.18M | 191.68M | |
| Tangible asset value | 182.63M | 181.46M | 160.26M | 162.37M | 167.4M | |
| Net current asset value | 86.52M | 110.07M | 106.23M | 115.28M | 118.48M | |
| Invested capital | 0.16 | 0.17 | 0.16 | 0.16 | 0.14 | |
| Average receivables | 42.08M | 44.18M | 47.01M | 49.95M | 52.01M | |
| Average payables | 22.15M | 21.73M | 23.64M | 24.13M | 25.95M | |
| Average inventory | 44.94M | 47.39M | 52.13M | 58.65M | 64.9M | |
| Days sales outstanding | 43.65 | 43.95 | 43.13 | 47.18 | 44.35 | |
| Days payables outstanding | 78.15 | 88.78 | 89.5 | 90.45 | 89.63 | |
| Days of inventory on hand | 180.4 | 184.06 | 209.17 | 228.1 | 222.48 | |
| Receivables turnover | 2.06 | 2.05 | 2.09 | 1.91 | 2.03 | |
| Payables turnover | 1.15 | 1.01 | 1.01 | 1 | 1 | |
| Inventory turnover | 0.5 | 0.49 | 0.43 | 0.39 | 0.4 | |
| ROE | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Capex per share | -0.09 | -0.05 | -0.71 | -0.08 | -0.06 |
ATRC Frequently Asked Questions
What is AtriCure, Inc. stock symbol ?
AtriCure, Inc. is a US stock , located in Mason of Oh and trading under the symbol ATRC
What is AtriCure, Inc. stock quote today ?
AtriCure, Inc. stock price is $23.05 today.
Is AtriCure, Inc. stock public?
Yes, AtriCure, Inc. is a publicly traded company.
Company Profile
- Volume Average 680.72K
- Market Capitalization 1.17B
- Employee 1.2K
- CEO Mr. Michael H. Carrel
- Headquarters Mason,OH,US
- IPO Date 2005-08-05
-
Website
https://www.atricure.com 
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
